Small Molecules, Antibodies
Total Trials
21
As Lead Sponsor
18
As Collaborator
3
Total Enrollment
1,248
NCT00709514
Clinical Evaluation of DCB-WH1 in Healing of Chronic Diabetic Foot Ulcers
Phase: Phase 2
Role: Lead Sponsor
Start: Dec 31, 2008
Completion: Mar 31, 2012
NCT01898923
Evaluate the Efficacy and Safety of ON101 Cream for the Treatment of Chronic Diabetic Foot Ulcers
Phase: Phase 3
Start: Nov 23, 2012
Completion: May 11, 2020
NCT02353273
The Pharmacokinetic Study of WH-1 Ointment in Subjects With Chronic Diabetic Foot Ulcers
Phase: Phase 1
Start: Jul 22, 2015
Completion: Sep 5, 2016
NCT03890302
Evaluate the Safety, Tolerability, Pharmacokinetics,and Clinical Activity of FB704A
Role: Collaborator
Start: Mar 14, 2019
Completion: May 27, 2020
NCT05059509
Evaluate Efficacy of FB825 in Adults With Atopic Dermatitis
Start: Feb 6, 2020
Completion: Mar 31, 2022
NCT04413942
Evaluate Efficacy, PK, and Safety of FB825 in Adults With Atopic Dermatitis
Start: Mar 10, 2020
Completion: Jun 30, 2022
NCT02347228
Evaluate Safety, Tolerability, PK, Preliminary Clinical Activity of OB318 in Patients With Advanced Solid Malignancies
Start: Sep 11, 2020
Completion: Dec 31, 2024
NCT04945161
A Randomized,Double-blind,Placebo-controlled Clinical Study to Explore the Mechanism of Action of ON101 Cream in Patients With DFUs.
Phase: N/A
Start: Feb 23, 2021
Completion: Dec 24, 2021
NCT05322525
A Research Study to Evaluate the Safety and Potential Efficacy of ON101 Cream for the Treatment of Venous Leg Ulcers.
Phase: Phase 4
Start: Jun 23, 2021
Completion: Aug 15, 2023
NCT04962139
Evaluate the Safety and Efficacy of ON101 Cream for the Treatment of Chronic Diabetic Foot Ulcers
Start: Jul 27, 2021
Completion: Nov 29, 2022
NCT05008965
Evaluate the Efficacy and Safety of FB825 in Adult With Allergic Asthma
Completion: Jun 30, 2024
NCT05018299
Evaluate the Efficacy and Safety of FB704A in Adult With Severe Asthma
Start: Sep 30, 2021
Completion: Sep 30, 2025
NCT05135130
Retrospective Record-review Study in Patients Who Had Diabetic Foot Ulcer
Start: Oct 4, 2021
Completion: Jan 31, 2022
NCT05338463
Fespixon Cream for the Treatment of Chronic Diabetic Foot Ulcers (TEXAS 1A, 2A) in Dialysis Patients
Start: Dec 1, 2021
Completion: Mar 22, 2024
NCT05317442
Open-label Study to Evaluate the Efficacy and Safety of Fespixon Cream for the Treatment of Pressure Injury in Sacrum and Greater Trochanter Wound
Start: Apr 6, 2022
Completion: Apr 19, 2024
NCT05438251
Exploring the Effect of Fespixon Cream for the Treatment of Diabetic Foot Ulcers (TEXAS 3A, 3B)
Start: Aug 4, 2022
Completion: Apr 3, 2024
NCT05677893
A Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of Inhaled MBS-COV (SNS812) in Healthy Participants
Start: Nov 7, 2022
Completion: Mar 30, 2023
NCT05952986
A Study to Evaluate the Safety and Bridging PK Profile of FB825 for Single Subcutaneous Administration in Healthy Adults
Start: May 3, 2023
Completion: Mar 26, 2024
NCT05941793
A Study to Evaluate the Efficacy, Safety, and Concentration of SNS812 in Mild to Moderate COVID-19 Patients
Start: Sep 11, 2023
Completion: Aug 12, 2024
NCT06397911
Evaluate Efficacy and Safety of Repeat Subcutaneous Doses of FB825 in Adults With Moderate-to-Severe Atopic Dermatitis
Start: Aug 8, 2024
Completion: Jun 30, 2026
NCT06531512
Evaluate the Efficacy and Safety of Xianglei Tangzu Gao for the Treatment of Wagner Grade II Diabetic Foot Ulcers
Phase: Phase 2/3
Start: Aug 16, 2024
Completion: Mar 31, 2026
Loading map...